Plavix sales help thicken BMS’s profits
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbswung into a healthy fourth-quarter profit with strong sales of Plavix (clopidogrel bisulfate). The blood thinner had worldwide sales of $1.47 billion during the fourth quarter, an increase of 7%.